\
&
Contact us
\
&
Contact us
A deep dive into specific issues and answers to commonly asked questions. This section is regularly updated
This infosheet is meant to remind applicants of the additional eligibility rules that apply to Cluster 3 calls and to avoid typical mistakes regarding practitioners' participation.
Open Access to peer-review scientific publications is one of the mandatory Open Science requirements under Horizon Europe.
The article 22.5 eligibility requirements establish ownership and control restrictions designed to protect the strategic interests of the European Union. This infosheet provides a comprehensive overview of what you need to know as an applicant.
The CA is a private, legally binding contract between all beneficiaries of a Horizon Europe project. It regulates the internal organisation, rights and obligations of the consortium as a whole and it's members individually.
What exactly is a cascade call? What can you expect from these calls?
Access to tailor-made coaching, mentoring, expertise and training delivered by specialised providers and adapted to your innovation stage.
This infosheet on international cooperation provides an overview of all types of countries for Horizon Europe participation and its eligibilty.
This infosheet provides an overview of the timeline towards the next EU Framework Programme for research & innovation as well as an overview of position and discussion papers that have been published so far.
Certain calls for proposals require the submission of Ownership Control Declarations as mandatory annex to the application.
European Digital Infrastructure Consortia (EDICs) are a new instrument to implement Multi-Country Projects to achieve the objectives of Europe's Digital Decade.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
